Skip to main content
. Author manuscript; available in PMC: 2019 Aug 15.
Published in final edited form as: Eur J Pharmacol. 2018 Jun 7;833:190–200. doi: 10.1016/j.ejphar.2018.06.010

Figure 3. Development of 20-HETE-related pharmaceutical agents.

Figure 3.

20-HETE-related pharmaceutical agents are summarized, including CYP inhibitors and inducers, and 20-HETE agonists and antagonists. Chronologically, these compounds became more potent, specific, and soluble with development. Abbreviations: 17-ODYA: 17-octadecynoic acid; ABT: 1-aminobenzotriazole; DBDD: 12, 12-dibromododec-11-enamide; DDMS: N-methylsulfonyl-12, 12-dibromododec-11-enamide; HET-0016: N-hydroxy-N’-(4-n-butyl-2-methylphenyl) formamidine; TS011: N-(3-Chloro-4-morpholin-4-yl) Phenyl-N’-hydroxyimido formamide; 5, 14–20-HEDE or WIT-003: 20-hydroxyeicosa-5(Z), 14(Z)-dienoic acid; 5, 14–20-HEDGE: N-[20-hydroxyeicosa-5(Z), 14(Z)-dienoyl] glycine; 6,15–20-HEDE or WIT-002: 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid; 20-SOLA: 2, 5, 8, 11, 14, 17-hexaoxanonadecan-19-yl 20-hydroxyeicosa-6(Z), 15(Z)-dienoate; AAA: sodium (S)-2-((6Z,15Z)-20-hydroxyicosa-6,15-dienamido)- succinate.